Sinopharm, a state-controlled firm said that a vaccine candidate made by its Beijing Institute of Biological Products arm had an efficacy rate of 79%
A woman is vaccinated with a syringe of a Chinese COVID-19 vaccine, developed by medicine company Sinopharm, by a nurse during the mass COVID-19 vaccination process at the Exhibition Center, in Manama, Bahrain on December 19, 2020;Image: Ayman Yaqoob/Anadolu Agency via Getty Images
©2019 New York Times News Service